Literature DB >> 19841906

Comparative study of five antiepileptic drugs on a translational cognitive measure in the rat: relationship to antiepileptic property.

Guy A Higgins1, Nathalie Breysse, Elijus Undzys, D Richard Derksen, Melanie Jeffrey, Brian W Scott, Tao Xin, Corinne Roucard, Karine Bressand, Antoine Depaulis, W M Burnham.   

Abstract

RATIONALE: Antiepileptic drugs (AEDs) have been available for many years; yet, new members of this class continue to be identified and developed due to the limitations of existing drugs, which include a propensity for cognitive impairment. However, there is little preclinical information about the cognitive effects they produce, which clinically include deficits in attention and slowing of reaction time.
OBJECTIVES: The purpose of this study was to profile two first-generation AEDs, phenytoin and valproate, and three second-generation AEDs, levetiracetam, pregabalin and lacosamide. Initially, each drug was examined across a range of well characterised preclinical seizure tests, and then each drug was evaluated in the five-choice serial reaction time test (5-CSRTT) based on efficacious doses from the seizure tests.
MATERIALS AND METHODS: Each AED was tested for anti-seizure efficacy in either (1) the maximal electroshock seizure test, (2) s.c. PTZ seizure test, (3) amygdala-kindled seizures and (4) the genetic absence epilepsy rat of Strasbourg model of absence seizures. On completion of these studies, each drug was tested in rats trained to asymptotic performance in the 5-CSRTT (0.5 s SD, 5 s ITI, 100 trials). Male rats were used in all studies.
RESULTS: Each AED was active in at least one of the seizure tests, although only valproate was active in each test. In the 5-CSRT test, all drugs with the exception of levetiracetam, significantly slowed reaction time and increased omissions. Variable effects were seen on accuracy. The effect on omissions was reversed by increasing stimulus duration from 0.5 to 5 s, supporting a drug-induced attention deficit. Levetiracetam had no negative effect on performance; indeed, reaction time was slightly increased (i.e. faster).
CONCLUSIONS: These results highlight somewhat similar effects of phenytoin, valproate, pregabalin and lacosamide on attention and reaction time, and comparison to efficacious doses from the seizure tests support the view that there may be a better separation with the newer AEDs. Levetiracetam had no detrimental effect in the 5-CSRTT, which may be consistent with clinical experience where the drug is considered to be well tolerated amongst the AED class.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19841906     DOI: 10.1007/s00213-009-1682-5

Source DB:  PubMed          Journal:  Psychopharmacology (Berl)        ISSN: 0033-3158            Impact factor:   4.530


  49 in total

1.  Cognitive and behavioral effects of antiepileptic drugs.

Authors:  K J Meador; F G Gilliam; A M Kanner; J M Pellock
Journal:  Epilepsy Behav       Date:  2001-08       Impact factor: 2.937

2.  Effects of antiepileptic drugs on working memory as assessed by spatial alternation performance in rats.

Authors:  Harlan E Shannon; Patrick L Love
Journal:  Epilepsy Behav       Date:  2004-12       Impact factor: 2.937

Review 3.  Translational research in central nervous system drug discovery.

Authors:  Orest Hurko; John L Ryan
Journal:  NeuroRx       Date:  2005-10

Review 4.  Development of new antiepileptic drugs: challenges, incentives, and recent advances.

Authors:  Emilio Perucca; Jacqueline French; Meir Bialer
Journal:  Lancet Neurol       Date:  2007-09       Impact factor: 44.182

5.  The influence of antiepileptic drugs on cognition: a comparison of levetiracetam with topiramate.

Authors:  Bettina Gomer; Kathrin Wagner; Lars Frings; Josef Saar; Astrid Carius; Markus Härle; Bernhard J Steinhoff; Andreas Schulze-Bonhage
Journal:  Epilepsy Behav       Date:  2007-04-03       Impact factor: 2.937

Review 6.  The 5-choice serial reaction time task: behavioural pharmacology and functional neurochemistry.

Authors:  T W Robbins
Journal:  Psychopharmacology (Berl)       Date:  2002-08-09       Impact factor: 4.530

7.  Lacosamide, a novel anti-convulsant drug, shows efficacy with a wide safety margin in rodent models for epilepsy.

Authors:  Thomas Stöhr; Harvey J Kupferberg; James P Stables; Daeock Choi; Robert H Harris; Harold Kohn; Nancy Walton; H Steve White
Journal:  Epilepsy Res       Date:  2007-04-12       Impact factor: 3.045

Review 8.  Pharmacological and therapeutic properties of valproate: a summary after 35 years of clinical experience.

Authors:  Emilio Perucca
Journal:  CNS Drugs       Date:  2002       Impact factor: 5.749

Review 9.  The neurobiology of antiepileptic drugs for the treatment of nonepileptic conditions.

Authors:  Michael A Rogawski; Wolfgang Löscher
Journal:  Nat Med       Date:  2004-07       Impact factor: 53.440

10.  The investigational anticonvulsant lacosamide selectively enhances slow inactivation of voltage-gated sodium channels.

Authors:  Adam C Errington; Thomas Stöhr; Cara Heers; George Lees
Journal:  Mol Pharmacol       Date:  2007-10-16       Impact factor: 4.436

View more
  3 in total

1.  Current and emerging treatments for absence seizures in young patients.

Authors:  Pascal Vrielynck
Journal:  Neuropsychiatr Dis Treat       Date:  2013-07-15       Impact factor: 2.570

2.  Effects of Lacosamide Treatment on Epileptogenesis, Neuronal Damage and Behavioral Comorbidities in a Rat Model of Temporal Lobe Epilepsy.

Authors:  Michaela Shishmanova-Doseva; Dimitrinka Atanasova; Yordanka Uzunova; Lyubka Yoanidu; Lyudmil Peychev; Pencho Marinov; Jana Tchekalarova
Journal:  Int J Mol Sci       Date:  2021-04-28       Impact factor: 5.923

3.  The influence of levetiracetam in cognitive performance in healthy individuals: neuropsychological, behavioral and electrophysiological approach.

Authors:  Julio Cesar Magalhães; Mariana Gongora; Renan Vicente; Juliana Bittencourt; Guaraci Tanaka; Bruna Velasques; Silmar Teixeira; Gledys Morato; Luis F Basile; Oscar Arias-Carrión; Fernando A M S Pompeu; Mauricio Cagy; Pedro Ribeiro
Journal:  Clin Psychopharmacol Neurosci       Date:  2015-04-30       Impact factor: 2.582

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.